MetaVia Inc. (MTVA)

MetaVia Inc. (MTVA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $9.6M; returns 1 day -0.7%, 1 week +9.5%, 1 year -86.9%.

MetaVia Inc. (MTVA), a clinical-stage biotechnology company, focuses on transforming cardiometabolic diseases. Their lead drug candidate, DA-1726, is a novel oxyntomodulin analogue that acts as a dual GLP1R and GCGR agonist in development for treating obesity. MetaVia also has Vanoglipel (DA-1241) in its pipeline.

Groups MTVA belongs to

• Biotechnology
• Recent Reverse Splits
• Clinical Stage Biotech
• Healthcare
• Clinical Stage
• Metabolic Disorders
• GLP-1 Agonists
• Weight Management
• Life Sciences
• Cardiovascular Therapies
• R&D

MTVA financial model: income statement, cash flow and balance sheet